Literature DB >> 29325769

The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D2 receptor.

Christopher J Draper-Joyce1, Mayako Michino2, Ravi Kumar Verma2, Carmen Klein Herenbrink1, Jeremy Shonberg3, Anitha Kopinathan3, Peter J Scammells3, Ben Capuano3, David M Thal1, Jonathan A Javitch4, Arthur Christopoulos1, Lei Shi5, J Robert Lane6.   

Abstract

SB269652 is a negative allosteric modulator of the dopamine D2 receptor (D2R) yet possesses structural similarity to ligands with a competitive mode of interaction. In this study, we aimed to understand the ligand-receptor interactions that confer its allosteric action. We combined site-directed mutagenesis with molecular dynamics simulations using both SB269652 and derivatives from our previous structure activity studies. We identify residues within the conserved orthosteric binding site (OBS) and a secondary binding pocket (SBP) that determine affinity and cooperativity. Our results indicate that interaction with the SBP is a requirement for allosteric pharmacology, but that both competitive and allosteric derivatives of SB269652 can display sensitivity to the mutation of a glutamate residue (E952.65) within the SBP. Our findings provide the molecular basis for the differences in affinity between SB269652 derivatives, and reveal how changes to interactions made by the primary pharmacophore of SB269652 in the orthosteric pocket can confer changes in the interactions made by the secondary pharmacophore in the SBP. Our insights provide a structure-activity framework towards rational optimization of bitopic ligands for D2R with tailored competitive versus allosteric properties.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allosteric modulation; Bitopic ligands; Dopamine receptor; G protein-coupled receptor; Molecular dynamics simulations; Mutagenesis

Mesh:

Substances:

Year:  2018        PMID: 29325769      PMCID: PMC5800995          DOI: 10.1016/j.bcp.2018.01.002

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  36 in total

Review 1.  Allosteric modulation of G protein-coupled receptors.

Authors:  Lauren T May; Katie Leach; Patrick M Sexton; Arthur Christopoulos
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

2.  Molecular determinants of biased agonism at the dopamine D₂ receptor.

Authors:  Dietmar Weichert; Ashutosh Banerjee; Christine Hiller; Ralf C Kling; Harald Hübner; Peter Gmeiner
Journal:  J Med Chem       Date:  2015-03-12       Impact factor: 7.446

3.  Structural basis for Na(+)-sensitivity in dopamine D2 and D3 receptors.

Authors:  Mayako Michino; R Benjamin Free; Trevor B Doyle; David R Sibley; Lei Shi
Journal:  Chem Commun (Camb)       Date:  2015-05-21       Impact factor: 6.222

4.  Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor.

Authors:  Nuska Tschammer; Stefan Bollinger; Terry Kenakin; Peter Gmeiner
Journal:  Mol Pharmacol       Date:  2010-12-16       Impact factor: 4.436

5.  The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors.

Authors:  Elena Silvano; Mark J Millan; Clotilde Mannoury la Cour; Yang Han; Lihua Duan; Suzy A Griffin; Robert R Luedtke; Gabriella Aloisi; Mario Rossi; Francesca Zazzeroni; Jonathan A Javitch; Roberto Maggio
Journal:  Mol Pharmacol       Date:  2010-08-11       Impact factor: 4.436

6.  CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields.

Authors:  K Vanommeslaeghe; E Hatcher; C Acharya; S Kundu; S Zhong; J Shim; E Darian; O Guvench; P Lopes; I Vorobyov; A D Mackerell
Journal:  J Comput Chem       Date:  2010-03       Impact factor: 3.376

7.  Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles.

Authors:  Robert B Best; Xiao Zhu; Jihyun Shim; Pedro E M Lopes; Jeetain Mittal; Michael Feig; Alexander D Mackerell
Journal:  J Chem Theory Comput       Date:  2012-07-18       Impact factor: 6.006

Review 8.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Arthur Christopoulos; Craig W Lindsley
Journal:  Nat Rev Drug Discov       Date:  2009-01       Impact factor: 84.694

9.  AUTOMATED FORCE FIELD PARAMETERIZATION FOR NON-POLARIZABLE AND POLARIZABLE ATOMIC MODELS BASED ON AB INITIO TARGET DATA.

Authors:  Lei Huang; Benoît Roux
Journal:  J Chem Theory Comput       Date:  2013-08-13       Impact factor: 6.006

10.  Activation and allosteric modulation of a muscarinic acetylcholine receptor.

Authors:  Andrew C Kruse; Aaron M Ring; Aashish Manglik; Jianxin Hu; Kelly Hu; Katrin Eitel; Harald Hübner; Els Pardon; Celine Valant; Patrick M Sexton; Arthur Christopoulos; Christian C Felder; Peter Gmeiner; Jan Steyaert; William I Weis; K Christopher Garcia; Jürgen Wess; Brian K Kobilka
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

View more
  8 in total

1.  The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists.

Authors:  Francisco O Battiti; Sophie L Cemaj; Adrian M Guerrero; Anver Basha Shaik; Jenny Lam; Rana Rais; Barbara S Slusher; Jeffery R Deschamps; Greg H Imler; Amy Hauck Newman; Alessandro Bonifazi
Journal:  J Med Chem       Date:  2019-07-01       Impact factor: 7.446

2.  2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.

Authors:  Amy Hauck Newman; Francisco O Battiti; Alessandro Bonifazi
Journal:  J Med Chem       Date:  2019-09-24       Impact factor: 7.446

3.  Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.

Authors:  Pramisha Adhikari; Bing Xie; Ana Semeano; Alessandro Bonifazi; Francisco O Battiti; Amy H Newman; Hideaki Yano; Lei Shi
Journal:  Biomolecules       Date:  2021-04-13

Review 4.  The Impact of the Secondary Binding Pocket on the Pharmacology of Class A GPCRs.

Authors:  Attila Egyed; Dóra Judit Kiss; György M Keserű
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

5.  Design, synthesis and biological evaluation of novel orthosteric-allosteric ligands of the cannabinoid receptor type 2 (CB2R).

Authors:  Rebecca Ferrisi; Francesca Gado; Beatrice Polini; Caterina Ricardi; Kawthar A Mohamed; Lesley A Stevenson; Gabriella Ortore; Simona Rapposelli; Giuseppe Saccomanni; Roger G Pertwee; Robert B Laprairie; Clementina Manera; Grazia Chiellini
Journal:  Front Chem       Date:  2022-09-27       Impact factor: 5.545

6.  Ligand with Two Modes of Interaction with the Dopamine D2 Receptor-An Induced-Fit Mechanism of Insurmountable Antagonism.

Authors:  Richard Ågren; Hugo Zeberg; Tomasz Maciej Stępniewski; R Benjamin Free; Sean W Reilly; Robert R Luedtke; Peter Århem; Francisco Ciruela; David R Sibley; Robert H Mach; Jana Selent; Johanna Nilsson; Kristoffer Sahlholm
Journal:  ACS Chem Neurosci       Date:  2020-09-15       Impact factor: 4.418

7.  Evidence for Two Modes of Binding of the Negative Allosteric Modulator SB269,652 to the Dopamine D2 Receptor.

Authors:  Richard Ågren; Kristoffer Sahlholm
Journal:  Biomedicines       Date:  2021-12-23

8.  Allosteric modulation of dopamine D2L receptor in complex with Gi1 and Gi2 proteins: the effect of subtle structural and stereochemical ligand modifications.

Authors:  Justyna Żuk; Damian Bartuzi; Andrea G Silva; Monika Pitucha; Oliwia Koszła; Tomasz M Wróbel; Dariusz Matosiuk; Marián Castro; Agnieszka A Kaczor
Journal:  Pharmacol Rep       Date:  2022-01-22       Impact factor: 3.024

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.